Our Pipeline

Jabez is advancing a focused pipeline of rational, synergistic cancer therapies: beginning with JBZ-001, an oral DHODH inhibitor currently in Phase 1 clinical development.

JBZ-001 is just the beginning of a scalable, clinically grounded development strategy. Our approach is driven by the 3-S model: selecting therapeutics that have seamless administration, scalable manufacturing, and synergize with existing standards of care.

PROGRAM

STRATEGY

INDICATION

PRECLINICAL

PHASE 1

PHASE 2

PHASE 3

DETAILS

JBZ-001 single-agent

Advanced Solid Tumors & Non-Hodgkin’s Lymphoma

Learn More

Dose escalation (part A) currently underway. Indication expansion (part B) expected to include NHL, and up to 3 others.

JBZ-001

Learn More

JBZ-001 is a small molecule inhibitor of DHODH.

JBZ-001 Single Agent

TP53-mutant Acute Myeloid Leukemia (AML)

Learn More

IND approved. Expected trial initiation: Q2 2026.

Investigator Sponsored Trial

UPMC, The James OSU Comprehensive Cancer Center, UC Medical Center

JBZ-001 single agent post-allo-HSCT

AML (subtype independent)

Learn More

Trial details coming soon.

JBZ-001 +
αCD38 mAbs

r/r Multiple Myeloma

Learn More

Trial details coming soon.

JBZ-002

Learn More

JBZ-002 is a small molecule inhibitor of DHODH

Treatment strategy is TBD

SCLC

Learn More

Trial details coming soon.

S.O.C. = Standard of care; mAbs = Monoclonal antibodies

CLINICAL DEVELOPMENT

Our Clinical Trials

Jabez Biosciences is proud to be a clinical-stage biotechnology company. We are currently enrolling patients in a Phase 1 clinical trial evaluating our lead candidate in advanced solid tumors and non-Hodgkin lymphoma.

Learn More About Clinical Trials

Our clinical partners: